Global Doxorubicin Market is expected to reach USD 1.38 billion by 2024. Doxorubicin is an anticancer chemotherapy drug, a generic name for the trade name drug Rubex® and Adriamycin®. It is injected into a vein. It is an essential medicine on the World Health Organization's List, the safest and effective medicines needed in a health system. The Doxorubicin Market is estimated to grow at a significant CAGR of 6.4% over the forecast period as the scope and its applications are rising enormously across the globe.
Growing presence of cancer patients across the globe, increasing number of manufacturers in the market to control the shortage of drugs, and developed laboratories with the latest technological equipment’s for research are documented as the major driving factors for Doxorubicin Market. Also, inclusion of doxorubicin drug in several applications like neuroblastoma, AIDS-related Kaposi Sarcoma, and others may boost the overall market in the years to come.
However, side effects of drugs and high cost of treatment are the factors that may restrain overall market growth in the coming years. Doxorubicin Industry is segmented based on formulation, cancer type, distribution channel, and region. Doxorubicin injection and lyophilized doxorubicin powder are the formulations that could be explored in Doxorubicin in the forecast period.
There are several types of cancer like Leukemia, Breast Cancer, Stomach Cancer, Prostate Cancer, Bladder Cancer, Ovary Cancer, Lung Cancer, and others that could be explored in Doxorubicin in the forecast period. Breast cancer and prostate cancer accounted for the majority market share in 2017 and are estimated to lead the overall market in the years to come. This may be because of rising number of people suffering from breast and prostate cancer.
The market may be categorized based on distribution channel like E-Commerce, Retail Pharmacies, Hospitals Pharmacies, and others could be explored in the forecast period. Globally, North America accounted for the substantial market share of Doxorubicin in 2017 and is estimated to continue with its dominance in the near future. The reason behind the overall market growth could be presence of developed healthcare infrastructure, presence of key manufacturers in the region, and increasing number of cancer epidemiology. The United States is a major consumer of Doxorubicin in this region.
Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at the fastest pace in the foremost period. The aspects that may be ascribed to the growth comprise rising pharmaceutical market, developing healthcare infrastructure and growing occurrence of cancer mainly gastric cancer and lung cancer among population. The developing countries like India, Japan, and China are the major consumers of Doxorubicin in this region.
The key players of Doxorubicin Market are Synbias Pharma, Pfizer Inc., MicroBiopharm Japan Co., Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Meiji Seika Pharma Co., Ltd. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As companies all over the world have to believe that alliance with a market would permit them proportional market existence and authority to declare the leadership position.
Doxorubicin Market: Application outlook (Market revenue in USD Million, 2013 - 2024)
• Ovarian cancer
• Multiple myeloma
• Kaposi Sarcoma
• Bone sarcoma
• Breast cancer
• Endometrial cancer
• Gastric cancer
• Liver cancer
• Kidney cancer
• Other cancer
Doxorubicin market regional outlook (Market revenue in USD Million, 2013 - 2024)
• North America
• Asia Pacific
• Latin America
• Middle East and Africa
• South Africa
Research Support Specialist, USA
FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...